China Biologic Products Holdings Inc (NASDAQ:CBPO) was the recipient of a significant drop in short interest in the month of June. As of June 30th, there was short interest totalling 1,052,200 shares, a drop of 18.4% from the May 30th total of 1,288,700 shares. Currently, 4.8% of the company’s stock are sold short. Based on an average trading volume of 218,900 shares, the short-interest ratio is presently 4.8 days.

Several large investors have recently made changes to their positions in the stock. Hillhouse Capital Advisors Ltd. purchased a new position in shares of China Biologic Products during the fourth quarter valued at approximately $208,844,000. FMR LLC boosted its position in shares of China Biologic Products by 64.6% during the fourth quarter. FMR LLC now owns 737,579 shares of the biopharmaceutical company’s stock valued at $55,990,000 after buying an additional 289,485 shares during the last quarter. FIL Ltd boosted its position in shares of China Biologic Products by 1.8% during the first quarter. FIL Ltd now owns 519,071 shares of the biopharmaceutical company’s stock valued at $47,365,000 after buying an additional 8,929 shares during the last quarter. Greenwoods Asset Management Ltd boosted its position in shares of China Biologic Products by 281.8% during the first quarter. Greenwoods Asset Management Ltd now owns 479,580 shares of the biopharmaceutical company’s stock valued at $43,762,000 after buying an additional 353,980 shares during the last quarter. Finally, BlackRock Inc. boosted its position in shares of China Biologic Products by 1.4% during the fourth quarter. BlackRock Inc. now owns 444,402 shares of the biopharmaceutical company’s stock valued at $33,734,000 after buying an additional 6,347 shares during the last quarter. 35.28% of the stock is currently owned by institutional investors.

China Biologic Products stock traded up $0.65 during mid-day trading on Friday, reaching $93.42. The stock had a trading volume of 54,580 shares, compared to its average volume of 139,510. China Biologic Products has a fifty-two week low of $60.08 and a fifty-two week high of $105.50. The company has a 50-day simple moving average of $92.68. The stock has a market cap of $3.68 billion, a price-to-earnings ratio of 23.24, a PEG ratio of 4.79 and a beta of 1.25.

China Biologic Products (NASDAQ:CBPO) last announced its quarterly earnings data on Friday, May 10th. The biopharmaceutical company reported $1.11 EPS for the quarter, beating the Zacks’ consensus estimate of $0.99 by $0.12. The firm had revenue of $129.78 million during the quarter, compared to analysts’ expectations of $119.50 million. China Biologic Products had a return on equity of 8.81% and a net margin of 27.71%. During the same quarter last year, the firm posted $1.21 earnings per share. As a group, equities research analysts predict that China Biologic Products will post 3.87 earnings per share for the current year.

CBPO has been the subject of a number of research reports. Zacks Investment Research raised Gerdau from a “sell” rating to a “hold” rating in a research note on Monday, May 13th. BidaskClub cut Weyco Group from a “sell” rating to a “strong sell” rating in a research note on Saturday. Finally, ValuEngine cut Zuora from a “buy” rating to a “hold” rating in a research note on Saturday, June 1st. Two investment analysts have rated the stock with a sell rating and four have assigned a hold rating to the stock. China Biologic Products has an average rating of “Hold” and a consensus price target of $78.00.

About China Biologic Products

China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.

Further Reading: Insider Trading – What You Need to Know

Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.